GI cancer update from ASCO 2025

Описание: GI CONNECT member Dr Lizzy Smyth joined us at ASCO 2025 to share her insights on new gastric cancer data from the MATTERHORN and DESTINY-Gastric04 studies presented at the congress.

How will this data impact clinical practice? Watch Dr Smyth’s update to find out.

Studies mentioned in this video:

MATTERHORN: Event-free survival in MATTERHORN: A randomised, Phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy in resectable gastric/gastroesophageal junction cancer. Janjigian Y, et al. Abstract LBA5, ASCO 2025

DESTINY-Gastric04: Trastuzumab deruxtecan vs ramucirumab + paclitaxel in second-line treatment of patients with HER2+ unresectable/metastatic gastric cancer or gastroesophageal junction adenocarcinoma: Primary analysis of the randomised, Phase 3 DESTINY-Gastric04 study. Shitara K, et al. Abstract LBA4002, ASCO 2025

Get more updates from ASCO 2025 in GU oncology, breast cancer, obstetrics and gynecology and lung cancer on our website: https://cor2ed.com/n-connect/programm...


Follow GI CONNECT on social media:

X - https://x.com/giconnectInfo

LinkedIn -   / giconnect  



Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.



This video was developed by https://cor2ed.com/

Published June 2025